RareCyte Inc., a Seattle-based life science company, closed the second tranche of its funding led by Telegraph Hill Partners (THP).
The company plans to use the funds to complete the final stages of product development and initiate the platform’s commercial launch in the research oncology market.
Founded in 2009 and led by Ron Seubert, President and CEO, RareCyte is focused on the development of the AccuCyteTM System, a rare cell characterization and retrieval platform based upon its proprietary whole blood enrichment technology and designed to target circulating tumor and circulating endothelial cells through an unbiased approach that results in high recovery and purity for additional downstream analysis of the cells.
FinSMEs
22/08/2012